Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement

All countries are encouraged to establish a paediatric screening programme to increase familial hypercholesterolaemia (FH) detection

Revised diagnostic criteria are presented, as current criteria often fail to identify children with an FH-causing genetic variant

Updated LDL-C treatment goals are proposed

Start lipid-lowering therapies before puberty in children with heterozygous FH (HeFH) and, if needed, from 6 years

Management guidance, including treatment algorithms for children with HeFH or homozygous FH (HoFH) and promotion of a smooth transition to adult care